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James M Peacock6, Alexander S Tretinyak5, Timothy D Henry5, Russell V Luepker7 and Alan T Hirsch2*Abstract
Background: Advanced lower extremity peripheral artery disease (PAD), whether presenting as acute limb ischemia
(ALI) or chronic critical limb ischemia (CLI), is associated with high rates of cardiovascular ischemic events,
amputation, and death. Past research has focused on strategies of revascularization, but few data are available that
prospectively evaluate the impact of key process of care factors (spanning pre-admission, acute hospitalization, and
post-discharge) that might contribute to improving short and long-term health outcomes.
Methods/Design: The FRIENDS registry is designed to prospectively evaluate a range of patient and health system
care delivery factors that might serve as future targets for efforts to improve limb and systemic outcomes for patients
with ALI or CLI. This hypothesis-driven registry was designed to evaluate the contributions of: (i) pre-hospital limb
ischemia symptom duration, (ii) use of leg revascularization strategies, and (iii) use of risk-reduction pharmacotherapies,
as pre-specified factors that may affect amputation-free survival. Sequential patients would be included at an index
“vascular specialist-defined” ALI or CLI episode, and patients excluded only for non-vascular etiologies of limb threat.
Data including baseline demographics, functional status, co-morbidities, pre-hospital time segments, and use of medical
therapies; hospital-based use of revascularization strategies, time segments, and pharmacotherapies; and rates of
systemic ischemic events (e.g., myocardial infarction, stroke, hospitalization, and death) and limb ischemic events
(e.g., hospitalization for revascularization or amputation) will be recorded during a minimum of one year follow-up.
Discussion: The FRIENDS registry is designed to evaluate the potential impact of key factors that may contribute to
adverse outcomes for patients with ALI or CLI. Definition of new “health system-based” therapeutic targets could then
become the focus of future interventional clinical trials for individuals with advanced PAD.
Keywords: Peripheral artery disease, Amputation, Atherosclerosis, Health service research, Outcomes researchBackground
Advanced lower extremity peripheral artery disease
(PAD) represents a relatively uncommon, but excep-
tionally high-risk, manifestation of systemic atheroscler-
osis. Both traditional PAD classification systems and
recent evidence-based PAD care guidelines have em-
phasized the potential benefit of more consistent case* Correspondence: hirsc005@umn.edu
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stated.classification of advanced PAD into two distinct clinical
syndromes, denoted as acute limb ischemia (ALI) or
chronic critical limb ischemia (CLI). Both PAD syn-
dromes represent manifestations of a severe comprom-
ise of arterial blood flow to the affected lower extremity,
with the acuity of onset of ischemia and specific clinical
signs used to distinguish between these syndromes [1].
In contrast to comparable acute coronary disease syn-
dromes (such as the acute coronary syndromes [ACS]
of non-ST segment myocardial infarction (MI) and
ST-elevation MI), the epidemiology of ALI and CLI is. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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based surveillance. Current evidence suggests an inci-
dence of approximately 430 to 1160 cases per million
individuals annually [2-4]. Although ALI and CLI repre-
sent the primary etiology of most lower-limb amputa-
tions [5] and are associated with high short-term rates
of systemic and limb ischemic events [6,7], uncertainty
regarding the incidence, prevalence, and outcomes of
the ALI and CLI syndromes is, in part, based on the lack
of a uniform and applicable definition used in either
field studies or in clinical practice outside of specialized
vascular centers.
Improvements in coronary ischemic syndrome health
outcomes have been facilitated by consistent use of ACS
definitions and subsequent evaluation of health system
factors that contribute to cardiovascular risk. For example,
improved outcomes for patients with ST-elevation MI and
acute stroke were achieved by evaluation of methods to
shorten end-organ ischemia time (including patient recog-
nition of heart attack symptoms and creation of expedited
referral systems) and this knowledge has been success-
fully encompassed in cardiac and stroke care guidelines
[8,9]. In contrast, little data exist to define the contribu-
tion of limb ischemia time to adverse limb or systemic
outcomes for individuals with ALI and CLI. Similarly,
whereas the impact of pharmacological and behavioral
risk-reduction interventions (e.g., use of antiplatelet and
statin medications) is well-defined for patients with
ACS, a knowledge gap exists regarding the potential
impact of these systemic treatments after successful leg
arterial revascularization. This knowledge gap is central
for patients with advanced PAD as recent data do-
cument that both endovascular and open surgical ap-
proaches, while effective in improving limb outcomes
for individuals with CLI [10], are still associated with
very high rates of heart attack, stroke, and cardiovascu-
lar death within one year of an index CLI presentation.
Randomized clinical trials (RCTs) provide the most ro-
bust methodological approach to determining the effi-
cacy, harm, and net impact of potential treatments for
individuals with advanced PAD. Nevertheless, recent
experience has demonstrated the challenges and costs
associated with recruitment of individuals with ALI and
CLI into prospective RCTs. As for coronary disease or
heart failure clinical research, there are potential ad-
vantages to the study of outcome determinants from a
prospective disease registry. These advantages include:
enrollment of the full patient cohort with minimal exclu-
sion criteria, the use of a multicenter design that is often
more broadly representative of the ALI and CLI popula-
tion than might be recruited from specialized centers
that participate in sponsored RCTs, the potential to cap-
ture longer-term outcomes data, the ability to pre hoc de-
fine outcome determinants (e.g., pre-hospital leg ischemiatime) that are not easily evaluated in a RCT context, and
often the ability to collect such data at lower cost [11-13].
In this context, specific knowledge gaps regarding de-
terminants of adverse health outcomes for individuals
with ALI and CLI were used to design a hypothesis-
driven clinical registry. The primary aim of the FRIENDS
registry is to evaluate a pre-defined set of patient and
health system factors on one-year rates of systemic and
limb ischemic events, and thus on amputation-free sur-
vival. These factors included: (i) pre-hospital limb ische-
mia symptom duration, (ii) use of leg revascularization
strategies, and (iii) use of risk-reduction pharmacother-
apies. Outcome events (rates of non-fatal MI, stroke,
amputation, and death) will be collected at one month, six
months, and one year. Secondary study aims are to assess:
(a) the relative frequency and etiology of the ALI and CLI
diagnoses in a large community-derived population, (b)
the frequency of use of evidence-based risk-reduction
medication in this high-risk population at baseline and
during follow-up, (c) predictors of functional status, and
(d) rates of systemic ischemic events. The FRIENDS regis-
try structure was pre hoc designed to serve as a pilot study
for future implementation of a multicenter registry to
prospectively evaluate the impact of standards of care on
health outcomes for all individuals with ALI and CLI.
Methods/Design
Study design
The registry is designed as a prospective cohort evalu-
ation of individuals with advanced PAD, defined as in-
clusive of the ALI and CLI syndromes.
Enrollment
We defined the index hospitalization as the first presenta-
tion for ALI or CLI, since a hospital admission serves as
an easily identified site for detection of such cases. Use of
an index hospitalization is also advantageous (as compared
to recruitment from vascular specialty clinics or wound
centers) since it defines a population in whom health care
resource utilization is high and in which quality outcomes
staff now exist to facilitate initial and subsequent out-
comes data collection. Patient enrollment is intended to
be sequential and fully inclusive, with exclusions limited
to non-provision of informed consent that are docu-
mented by a screening log.
Definition of advanced PAD syndromes
The registry was designed to utilize definitions of ad-
vanced PAD (ALI and CLI) that are encompassed in the
intersocietal “ACC/AHA Guidelines for the Management
of Patients with PAD” [1] and concordant TASC-II [2]
PAD guidelines. As such, ALI is clinically defined by the
admitting vascular specialist in patients who experience
the clinical stigmata associated with acute ischemia and a
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14 days in duration. Using this guideline-derived ALI case
classification, enrollment of patients is achieved via docu-
mentation of acute limb ischemic symptoms and signs
(the 6 “Ps”) (Table 1). CLI will be defined, per these PAD
clinical care guidelines, in patients with Rutherford class 4,
5, or 6 manifestations such as ischemic rest pain, and
minor or major tissue loss of greater than two weeks dur-
ation. At enrollment, patients with ALI and CLI will
undergo evaluation of an objective pedal or toe pressure
measurement when this is feasible pre-revascularization.
Source documents have been created so that collection of
these entry criteria, as applied by participating clinicians,
will be uniformly obtained.
Use of source documents and data abstraction
This is a prospective registry, and as such all sequential
eligible patients with ALI or CLI who are hospitalized
(defined as requiring an index leg revascularization pro-
cedure or overnight stay) will be entered into the registry.
Medical record documentation will be required immedi-
ately on admission (not retrospectively) for establishment
of the presence of ALI or CLI. Vascular specialty and hos-
pitalist staff will receive instruction on: (a) the clinical defi-
nitions of ALI and CLI, (b) how to complete a source
document on patient admission that includes the time of
onset of symptoms, and (c) the use of health system tools
(e.g., standardized order sets) to facilitate prompt meas-
urement of pedal or great toe pressures (Table 1).
A documented medical history of coronary artery disease
(CAD) will consist of 1 or more of any of the following
chart documented conditions or procedures: stable angina,
previous myocardial infarction, history of percutaneous cor-
onary intervention or history of coronary artery bypass graft
surgery. Documented cerebrovascular disease (CVD) will
be defined by a history of transient ischemic attack (TIA),
ischemic or hemorrhagic stroke, carotid stenting or carotid
endarterectomy. Documented prior PAD will be defined by
1 or more of the following criteria: symptomatic PAD
defined by history of claudication, asymptomatic PAD doc-
umented in the medical records, or history of ALI or CLI.Table 1 Inclusion criteria: Ischemic symptoms and signs, and
For all patients: Clinical
symptoms and signs
For ALI patients
of any of the
Ischemic rest pain Pain
Ulcer Pale
Gangrene Pulseles
Paresthe
Paralys
Poikilothe
Abbreviations: ABI Ankle-brachial index, TBI toe-brachial index.Baseline height and weight will be obtained from the
medical records, and body mass index (BMI) calculated.
Patients will be considered overweight if they have a
BMI of 25 kg/m2 to less than 30 kg/m2 or obese if they
have a BMI ≥30 kg/m2. Atherosclerosis risk factors will be
defined as present: if documented in the medical record, if
the patient is receiving treatment for the risk factor at the
time of study enrollment, or if there are supporting labora-
tory test data proximal to the index hospitalization. Dia-
betes will be considered present when there is chart
documentation, regardless of type (I or II), or when use
of an anti-diabetic medication or dietary intervention is
documented. As well, the documentation of fasting
blood glucose ≥7 mmol/l (126 mg/dl) will be considered
evidence of diabetes when these laboratory data are
available. Hypertension will be defined when chart doc-
umented or when there is evidence of treatment with
any antihypertensive medication or behavioral inter-
vention (e.g., use of calcium channel blockers, ACE-
inhibitors, beta blockers, diuretics or diet/exercise).
Dyslipidemia is considered present when there is chart
documentation or use of any lipid-lowering or choles-
terol modifying medication (e.g., statin, niacin, fibrates,
or bile acid binding resin agents). Dyslipidemia is also
considered to be present if, per the National Cholesterol
Education Program (NCEP) guidelines, the total choles-
terol concentration is >200 mg/dl (5.18 mmol/l), LDL
concentration is >130 mg/dl (3.37 mmol/l), and/or HDL
concentration is <40 mg/dl (1.04 mmol/l). Other criteria
for establishment of dyslipidemia include a fasting triglycer-
ide concentration of ≥200 mg/dl, or total cholesterol/HDL
ratio ≥5.0. Smoking status is recorded as “current” if any
cigarettes were used within one month of the encounter,
“former” if smoking had ceased more than one month prior
to the encounter, and “never” if there is no history of to-
bacco use. A family history of premature CAD consists of
any chart documentation of a family history of premature
CAD or any myocardial infarction (MI) in a first-degree
relative (men <55 years or women <65 years). The etiology
of ALI or CLI is coded from data obtained in the medical
record.objective limb pressure measurements at enrollment
: Presence
“6 Ps”
For all patients: Objective
pressure measurements
Pedal pressures
Great toe pressures
s Ankle-brachial index
sia Toe-brachial index
is
rmia
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obtained from patient self-report and supplemented by
abstracted medical record reports of treating clinicians.
There is at present no single well-accepted format for
recording ambulatory status in individuals with ALI and
CLI. Ambulatory status therefore will be categorized into
five groups and assigned ordinal values of 1 to 5, with 5
representing the best, and 1 the lowest, ambulatory status.
The highest class (5), “fully ambulatory”, is defined as the
ability to independently ambulate and fully interact in the
community. “Minimal ambulation” (4) is defined as ambu-
lation limited to within the house/hospital, around the
house/hospital, and to the mail box. “Ambulation with
assistance” (3) is defined by ambulation requiring another
person’s help for mobility. “Wheelchair bound” (2) is
defined by dependency on a wheelchair for all mobility.
“Bed bound” (1) is defined when the patient is not mobile
at all, is fully restricted, and non-ambulatory. Ambulatory
status at baseline is the level of function after onset of ALI
or CLI and within one week prior to admission. Data will
be abstracted by trained research staff and reviewed by
vascular physicians.
All data will be collected via a standardized case report
form and then entered into a password-protected data-
base. Data will be collected consistent with the intersoci-
etal “2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN
Key Data Elements and Definition for Peripheral Athero-
sclerotic Vascular Disease” standards [14]. Outcome events
will be reviewed and adjudicated by a clinical event com-
mittee consisting of individuals with expertise in vascular
surgery and vascular medicine. The registry design has
been approved by the local institutional review board at
the University of Minnesota and Allina Health System. All
included patients will provide written informed consent.
Patients screened for entry who do not offer informed con-
sent will be entered into a screening log.
Key time segments
The symptom onset of an initial episode of ALI/CLI is
defined by the patient’s self-report provided to the vas-
cular specialist at hospital admission, is dictated into the
encounter note, and this note (date and time) is later ab-
stracted from the medical records. Vascular specialists
(vascular surgeons, vascular medicine specialists, and
interventional radiologists) are instructed to document
the patient-reported index limb symptom onset within
pre-specified time parameters: within one hour for pa-
tients presenting within 3 days, within one day for pa-
tients presenting within 3 to 30 days, and within one
week for patients presenting greater than one month
since symptom onset. For CLI patients who cannot state
an exact time of leg symptom onset, it will be assumed
that the onset time is 12 noon on the day specified. Inas-
much as ALI or CLI is known to recur (repeat episodesare common), the index leg symptom is arbitrarily de-
fined as that which is temporally closest to the index
hospitalization. This approach is similar to that used for
ACS or stroke health services research.
While the pre-admission symptom duration serves as
the primary pre-defined hypothesized predictor of ad-
vanced PAD health outcomes, a number of other clinical
care time segments are considered of potential utility in
evaluation of the efficiency of hospital-based PAD care,
as it is known that CLI hospitalizations are lengthy
(greater than seven days) and expensive [15]. The
“admission to ABI/TBI” time segment is defined as the
time from hospital arrival to initiation of the first
hospital-based pedal or toe pressure measurement. The
“admission to heparin” time is defined as the time from
hospital arrival to the chart-documented initiation of a
therapeutic intravenous heparin infusion for patients so
treated. The “admission to vascular specialist at bedside”
time segment is defined as the time from hospital arrival
until the patient is evaluated by a vascular specialist, and
this is set by the time of the dictated note. The “admis-
sion to revascularization” time segment is defined as the
time from hospital arrival until the patient enters the
operating room or catheterization laboratory, and includes
only the use of an endovascular procedure, surgical pro-
cedure or primary amputation (medical treatment alone is
not included in this definition). Hospital length of stay is
defined as the number of days of hospitalization from
admission to discharge.
List of pre-specified “key time segments” for patients with
advanced peripheral artery disease
Symptom onset to admission
Admission to ABI/TBI measurement
Admission to IV heparin administration
Admission to vascular specialist at bedside
Admission to revascularization
Length of stay (days)
Study outcomes
The study outcomes that will be evaluated are summarized
in Table 2. The systemic ischemic risk clinical outcomes in-
clude: nonfatal MI, nonfatal stroke, cardiovascular (CV)
death, all-cause death, and cardiovascular re-hospitalization
event rates. The limb ischemic risk clinical outcomes
include: ALI or CLI recurrence, minor or major ampu-
tation, and total amputation event rates. These individ-
ual outcomes will be used to derive a composite triple
endpoint (defined as any nonfatal MI, stroke or amputa-
tion) and quadruple endpoint (defined as any non-fatal
MI, stroke, amputation or death). As well, the relevant
clinical outcome of “amputation-free survival” time will
be calculated at one year.
Table 2 Clinical evaluations on admission and at 1-, 6- and 12-month follow-up
Admission Hospital discharge 1 month 6 month 12 month
Demographic, clinical and functional characteristics, and key time segments
Demographic variables
Race, gender, education X
Marital and employment status X X X X X
Physical examination (weight, height, blood pressure, heart rate and rhythm) X
Laboratory values (serum creatinine, hemoglobin, fasting lipid profile) X
Etiology of ALI-CLI X
Key time segments (see ‘List of key time segments’) X X
Length of hospital stay X
Endovascular and open surgical procedures X
Ambulatory status X X X X X
Risk factors and risk-reduction therapies
Historical risk factors X
Use of risk-reduction pharmacotherapies X X X X X
Smoking status X X X X X
Outcome events
Amputation (major or minor) X X X X
Cardiovascular ischemic events (non-fatal MI and stroke), death X X X X
Recurrence of ALI-CLI X X X X
Other causes of hospitalization X X X
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the lower limb below the ankle and “major amputation” is
defined as removal of part of the lower limb above the
ankle. All-cause death is ascertained via the social security
death index (SSDI) in the USA or via other national death
registry systems using a combination of the social security
number (SSN), name and birth date to identify cases.
Searching the online SSDI, with a correct SSN provides an
accurate method to determine death as an outcome in clin-
ical research studies. A majority of subjects ordinarily lost
to followup including those with sudden death outside the
hospital can thus have their vital status accurately deter-
mined [16]. Cardiovascular death includes fatal stroke, fatal
MI, and other cardiovascular death. Other cardiovascular
death includes deaths of cardiac origin: death associated
with pulmonary embolism, vascular operation or proced-
ure, amputation (except for trauma or malignancy), heart
failure and visceral or limb infarction. Re-hospitalization
for CV events is defined as hospitalization for transient is-
chemic attack, unstable angina, worsening of PAD, CHF,
other ischemic arterial event or bleeding leading to both
hospitalization and transfusion. Recurrence of ALI/CLI is
defined as occurrence of any second episode of clinically di-
agnosed ALI/CLI and ascertained by medical chart review
at follow-up.
Follow-up will be performed primarily by phone calls
at 1 month (with a one week window), 6 months (with aone month window), and 12 months (with a two month
window) after hospital discharge using a phone script con-
taining standardized questions. The occurrence of non-
fatal MI, non-fatal stroke, amputation, re-hospitalization,
recurrence of ALI/CLI are ascertained by medical records,
all cause death by social security death index website [17],
and CV death by medical record review. Ambulatory sta-
tus will be ascertained by self-report during follow-up calls
and at return visits.
Determination of sample size
This is a hypothesis-generating registry from which pre-
liminary data will be obtained that will be key to refining
values used for estimating statistical power for future
multicenter clinical trials. It is anticipated that these data
may be useful in identifying medical, endovascular, and
health system interventions that could be tested in a
future randomized clinical trial, providing more accurate
estimates of expected detectable differences and their
standard deviations. Therefore, a formal power analysis
was not undertaken in the design of this pilot registry.
Statistical analysis
Descriptive statistics will be presented as means and
standard deviations for continuous variables, and fre-
quencies and percentages for categorical data. Conti-
nuous data that are not normally distributed will be
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will be analyzed as continuous variables, and also cate-
gorized to allow assessment of dose–response patterns.
Univariate models for all outcome variables with demo-
graphic, clinical and risk factor variables will be used to
elucidate potential confounding variables. Multivariable
logistic regression models will be used to assess the as-
sociation between key time variables and short-term bin-
ary outcomes (amputation, MI, stroke and death), with
adjustment for confounders. Survival analysis will be
performed using Kaplan-Meier methods for preliminary
analyses, and Cox proportional hazards models with
adjustment for confounders. Multiple linear regression
models will be used to assess the associations between
time segment variables and length of stay, with adjustment
for confounders. A two-sided p-value of <0.05 will be con-
sidered statistically significant. Data analysis will be per-
formed using Stata (Stata Inc, College Station, TX, USA).
Discussion
It is well-known that patients presenting with advanced
PAD bear a high burden of systemic ischemic events and
suffer an adverse limb prognosis, with very high health
economic impact [18]. Thus, care for patients with ad-
vanced PAD is a critical public health issue in the USA
and internationally [19]. Current epidemiological data
suggest that the incidence of ALI is 130 to 160 per mil-
lion per year [3,7] and the incidence of CLI is approxi-
mately 340 to 1000 per million per year [2,4]. Major
amputation rates at 30 days after clinical presentation
have been reported to be 10-30%, and death at one year
is reported to range from 16-42% for ALI patients [7,20].
Patients with CLI face a comparably dismal prognosis
and the annual amputation rate has been reported to
vary between 10% and 40% after a first diagnosis of CLI
[21]. Overall, one- and five-year mortality rates of pa-
tients with CLI are reported to be 20-25% and 40-70%,
respectively [22-24]. There are few cardiovascular dis-
eases with such adverse short-term outcomes. However,
diseases with high rates of adverse short term outcomes
are favorable for study within a disease registry frame.
The FRIENDS Registry was designed to enroll a high
volume of sequential patients with advanced PAD in order
to collect an adequate sample to permit evaluation of
the contributions of patient demographics, PAD etiology
(e.g., cardioembolism vs. graft failure), key time segments,
use of risk-reduction medications, and revascularization
strategies on functional status, rates of revascularization,
amputation, systemic ischemic event rates, and death.
These data will also provide the opportunity to determine
how clinicians in practice assess patients with advanced
PAD in real world (not clinical trial) settings, including
data that might define rates of adherence to current
evidence-based clinical care guidelines.We hypothesize that the current arbitrary 14 day diag-
nostic “time-based syndrome definition” that is often
used to differentiate ALI and CLI (beyond use of the 6
“Ps”) may not adequately discriminate these two syn-
dromes. The rationale for use of the 14-day timeframe
to define ALI has not been based on evidence as robust
as the data used to define the efficacy of acute MI or
stroke treatments. While there was a biological rationale
for setting an objective 14-day, time-based inclusion
criteria for study of catheter-directed thrombolysis in
individuals with acute arterial occlusion [20,25], this
time-based definition has been carried forward into sub-
sequent PAD care guidelines without corroborating the
utility of this approach for endovascular and open surgi-
cal techniques.
This registry provides an opportunity to assess whether
ALI or CLI are indeed two distinct clinical syndromes with
different etiologies and outcomes, or whether these trad-
itional clinical distinctions alternatively represent a time-
dependent continuum of advanced PAD.
More than 20 years ago, Panetta et al. [26] observed
that a longer duration of ischemia was associated with
increased amputation rates in ALI patients, and a more
recent study suggested that an increased duration of
limb ischemia was associated with more extensive gan-
grene [27]. Nevertheless, these observations were de-
rived from small cohorts, did not clarify a precise
vulnerable period, nor elucidate other factors that might
affect limb outcomes. This registry may provide insights
into factors that, along with prolonged pre-admission
limb ischemia, worsen prospects for limb survival. The
registry will also provide a contemporary description of
current etiologies of limb ischemia. For example, does
atrial fibrillation contribute to limb ischemic events at a
rate documented a decade ago, now that antithrombotic
therapies are more widely used? Is graft surveillance
used, per current national care guidelines, at rates
adequate to protect individuals who have undergone
prior successful limb revascularization?
During the last decade, cardiovascular care guidelines
have become an important cornerstone of the manage-
ment of heart disease and the positive impact of guidelines
is known [28]. In contrast, the development and dissemin-
ation of PAD care guidelines, including recommendations
regarding the ideal management of ALI and CLI, are rarely
evaluated prospectively [1,2]. These guidelines have re-
cognized that appropriate use of evidence-based risk-
reduction medication represents a major opportunity for
reducing future myocardial infarction, stroke, and death if
used in individuals with recognized PAD. However, recent
data have shown poor rates of use of evidence-based
risk-reduction medication on admission or discharge in
patients with CLI [10,29,30]. The registry will provide
an opportunity to evaluate the contemporary use of
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ischemic events in the PAD population at highest short-
term risk. We hypothesize that higher use of these med-
ications would offer a potentially major contribution to
improvement in rates of amputation-free survival; only
a prospective registry with an adequate cohort sample is
likely to provide such data, as a prospective RCT to
evaluate this hypothesis is currently unlikely. Data
further demonstrating such benefits of risk-reduction
medication use might then be considered for future
guideline inclusion, or within future PAD performance
standards [31].
Currently there are no standardized quality-of-life
instruments that are widely applied in populations of
individuals with critical limb ischemia. This registry of-
fers an opportunity to evaluate functional status on
admission, at discharge and at follow-up, as well as other
predictors of functional status at follow-up. While it is
known that poor ambulatory status on presentation is
associated with loss of primary patency and higher rates
of amputation at six months follow-up, other factors
beyond patency (e.g., avoidance of readmission, social
support, etc.) may contribute to the achievement of
improved functional outcomes [32].
Several limitations are inherent to this (or any) regis-
try. First, the enrollment of patients is intended to be
consecutive, but this is never fully achieved for any
registry. Nevertheless, the majority of the patients who
present for hospital care may be enrolled if, as planned,
both hospitalists and vascular specialists are engaged at
registry launch. Second, as for any registry, selection for
inclusion of a wide array of hospitals and health systems
can facilitate accrual of a representative cohort. Third,
any PAD registry is encumbered – in contrast to CAD
or stroke registries – by the inconsistent use of objective
diagnostic criteria in real world clinical practice (in con-
trast to RCTs). Whereas all individuals with an acute MI
undergo an ECG, it is not now clear whether individuals
with advanced PAD undergo consistent vascular labora-
tory testing. Thus, we have elected to initially permit the
inclusion of all “clinically diagnosed” ALI and CLI with-
out the requirement of pedal or toe pressure measure-
ments. Analysis of cohorts who have, or have not,
undergone such testing can demonstrate the utility of
this diagnostic approach. We note that the past diagnos-
tic inclusion criteria of an ankle pressure of ≤50 mmHg
[33] would potentially exclude two-thirds of patients
with CLI, as only 30% would fulfill the European Con-
sensus Guideline pedal pressure criteria, as observed in
the BASIL trial [34]. Thus, the registry will provide valu-
able information in a “real-world” setting by using
broader inclusion criteria. Pre hoc defined subgroup
analysis of the “clinical diagnosis” and “objective diagno-
sis” groups will provide insight regarding the value ofcurrent diagnostic pathways on choice of therapy and
achievement of positive outcomes.
In conclusion, a multicenter advanced PAD registry
may represent a significant opportunity to assess a series
of hypothesis-based factors that may modify systemic or
limb outcomes. In a manner analogous to methods used
to better understand the natural history and impact
of treatments for acute MI, stroke and heart failure,
advanced PAD registry data that includes pre-hospital
factors, revascularization strategies used during an index
hospitalization, and that evaluates long-term use of risk
modifying pharmacotherapies may provide new insights
to help the design of future PAD clinical trials.
Trial status
Recruitment for a multi-center CLI and ALI registry
began in February 2007 at a single center and will
continue at other centers, dependent upon funding.
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